CoChat

Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction

Open access
Nagels, Helen E, Rishworth, Josephine R, Siristatidis, Charalampos S, Kroon, Ben · 2015 · Cochrane Database of Systematic Reviews
Cited by 156

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Infertility is a condition affecting 10% to 15% of couples of reproductive age. It is generally defined as "the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse". The treatment of infertility may involve manipulation of gametes or of the embryos themselves. These techniques are together known as assisted reproductive technology (ART). Practitioners are constantly seeking alternative or adjunct treatments, or both, in the hope that they may improve the outcome of assisted reproductive techniques. This Cochrane review focusses on the adjunct use of synthetic versions of two naturally-produced hormones, dehydroepiandrosterone (DHEA) and testosterone (T), in assisted reproduction.DHEA and its derivative testosterone are steroid hormones proposed to increase conception rates by positively affecting follicular response to gonadotrophin stimulation, leading to greater oocyte yields and, in turn, increased chance of pregnancy. OBJECTIVES: To assess the effectiveness and safety of DHEA and testosterone as pre- or co-treatments in subfertile women undergoing assisted reproduction. SEARCH METHODS: We searched the following electronic databases, trial registers and websites up to 12 March 2015: the Cochrane Central Register of Controlled Trials (CENTRAL), the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, MEDLINE, EMBASE, PsycINFO, CINAHL, electronic trial registers for ongoing and registered trials, citation indexes, conference abstracts in the Web of Science, PubMed and OpenSIGLE. We also carried out handsearches. There were no language restrictions. SELECTION CRITERIA: We included randomised controlled trials (RCTs) comparing DHEA or testosterone as an adjunct treatment to any other active intervention, placebo, or no treatment in women undergoing assisted reproduction. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies, extracted relevant data and assessed them for risk of bias. We pooled studies using fixed-effect models. We calculated odds ratios (ORs) for each dichotomous outcome. Analyses were stratified by type of treatment. There were no data for the intended groupings by dose, mode of delivery or after one/more than one cycle.We assessed the overall quality of the evidence for the main findings using the GRADE working group methods. MAIN RESULTS: We included 17 RCTs with a total of 1496 participants. Apart from two trials, the trial participants were women identified as 'poor responders' to standard IVF protocols. The included trials compared either testosterone or DHEA treatment with placebo or no treatment.When DHEA was compared with placebo or no treatment, pre-treatment with DHEA was associated with higher rates of live birth or ongoing pregnancy (OR 1.88, 95% CI 1.30 to 2.71; eight RCTs, N = 878, I² statistic = 27%, moderate quality evidence). This suggests that in women with a 12% chance of live birth/ongoing pregnancy with placebo or no treatment, the live birth/ongoing pregnancy rate in women using DHEA will be between 15% and 26%. However, in a sensitivity analysis removing trials at high risk of performance bias, the effect size was reduced and no longer reached significance (OR 1.50, 95% CI 0.88 to 2.56; five RCTs, N = 306, I² statistic = 43%). There was no evidence of a difference in miscarriage rates (OR 0.58, 95% CI 0.29 to 1.17; eight RCTs, N = 950, I² statistic = 0%, moderate quality evidence). Multiple pregnancy data were available for five trials, with one multiple pregnancy in the DHEA group of one trial (OR 3.23, 95% CI 0.13 to 81.01; five RCTs, N = 267, very low quality evidence).When testosterone was compared with placebo or no treatment we found that pre-treatment with testosterone was associated with higher live birth rates (OR 2.60, 95% CI 1.30 to 5.20; four RCTs, N = 345, I² statistic = 0%, moderate evidence). This suggests that in women with an 8% chance of live birth with placebo or no treatment, the live birth rate in women using testosterone will be between 10% and 32%. On removal of studies at high risk of performance bias in a sensitivity analysis, the remaining study showed no evidence of a difference between the groups (OR 2.00, 95% CI 0.17 to 23.49; one RCT, N = 53). There was no evidence of a difference in miscarriage rates (OR 2.04, 95% CI 0.58 to 7.13; four RCTs, N = 345, I² = 0%, low quality evidence). Multiple pregnancy data were available for three trials, with four events in the testosterone group and one in the placebo/no treatment group (OR 3.09, 95% CI 0.48 to 19.98; three RCTs, N = 292, very low quality evidence).One study compared testosterone with estradiol and reported no evidence of a difference in live birth rates (OR 2.06, 95% CI 0.43 to 9.87; one RCT, N = 46, very low quality evidence) or miscarriage rates (OR 0.70, 95% CI 0.11 to 4.64; one RCT, N = 46, very low quality evidence).The quality of the evidence was moderate, the main limit

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd009749.pub2

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 62

  1. Artini, 2012, DHEA supplementation improves follicular microenvironment in poor responder patients, Gynecological Endocrinology, 28, 669-73
  2. Divita, 2003, Does dehidroepiandrosterone sulfate (Dheas) co-treatment improve art outcome? A prospective, randomized, double-blind placebo-controlled trial, Fertility and Sterility, 80 Suppl 3, S111, 10.1016/S0015-0282(03)02094-6 · doi:10.1016/s0015-0282(03)02094-6
  3. Fábregues, 2009, Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial, Human Reproduction, 24, 349, 10.1093/humrep/den428 · DOI · Paper page
  4. Kara, 2014, Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 173, 63, 10.1016/j.ejogrb.2013.11.008 · DOI
  5. Kara, 2013, Is dehydroepiandrosterone (DHEA) supplementation really effective on IVF-ICSI outcome in patients with poor ovarian reserve?, Fertility and Sterility, 100, S518, 10.1016/j.fertnstert.2013.07.246 · doi:10.1016/j.fertnstert.2013.07.246
  6. Kim, 2010, Ovarian features after 2 weeks, 3 weeks and 4 weeks transdermal testosterone gel treatment and their associated effect on IVF/ICSI outcome in low responders, Fertility and Sterility, 94, S155, 10.1016/j.fertnstert.2010.07.622 · doi:10.1016/j.fertnstert.2010.07.622
  7. Kim, 2011, The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders, Fertility and Sterility, 95, 679, 10.1016/j.fertnstert.2010.07.1077 · DOI
  8. Marzal, 2014, Antral follicle priming prior to ICSI in confirmed low responders: a randomized clinical trial (FOLLPRIM), Human Reproduction, 29, i25
  9. Massin, 2006, Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique--a prospective, randomized, double-blind study, Human Reproduction, 21, 1204, 10.1093/humrep/dei481 · DOI · Paper page
  10. Moawad, 2012, Long-term androgen priming by use of dehydroepiandrosterone (DHEA) improves IVF outcome in poor-responder patients. A randomized controlled study, Middle East Fertility Society Journal, 17, 268-74, 10.1016/j.mefs.2012.11.002 · DOI
  11. Tartagni, 2015, Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program, Minerva Ginecologica, 67, 7
  12. Tartagni, 2015, Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old, Reproductive Biology and Endocrinology, 13, 13, 10.1186/s12958-015-0014-3 · DOI
  13. Wiser, 2010, Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study, Human Reproduction, 25, 2496, 10.1093/humrep/deq220 · DOI · Paper page
  14. Yeung, 2013, A randomized double-blinded placebo-controlled trial on the effect of 16 weeks of dehydroepiandrosterone (DHEA) on ovarian reserve markers and IVF outcomes in normal responders, Fertility and Sterility, 100, S114, 10.1016/j.fertnstert.2013.07.1658 · doi:10.1016/j.fertnstert.2013.07.1658
  15. Yeung, 2013, A randomized double-blinded placebo-controlled trial on the effect of 16 weeks of dehydroepiandrosterone (DHEA) on ovarian reserve markers and IVF outcomes in poor responders, Fertility and Sterility, 100, S159, 10.1016/j.fertnstert.2013.07.1521 · doi:10.1016/j.fertnstert.2013.07.1521
  16. Yeung, 2014, A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders, Fertility and Sterility, 102, 108, 10.1016/j.fertnstert.2014.03.044 · DOI
  17. Zhang, 2014, Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial, Journal of Ovarian Research, 7, 93, 10.1186/s13048-014-0093-3 · DOI
  18. Balasch, 2006, Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH, Human Reproduction, 21, 1884, 10.1093/humrep/del052 · DOI · Paper page
  19. Barad, 2006, Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF, Human Reproduction, 21, 2845, 10.1093/humrep/del254 · DOI · Paper page
  20. Casson, 2000, Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series, Human Reproduction, 15, 2129, 10.1093/humrep/15.10.2129 · DOI · Paper page
  21. Santos, 2013, The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: is it hypoandrogenic?, Human Reproduction, 28, 224, 10.1093/humrep/des349 · DOI
  22. Fusi, 2013, DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function, Gynecological Endocrinology, 29, 940-3, 10.3109/09513590.2013.819087 · DOI
  23. Gleicher, 2013, Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR), Journal of Assisted Reproduction and Genetics, 30, 49, 10.1007/s10815-012-9890-z · DOI
  24. Hyman, 2010, Dehydroepiandrosterone (DHEA) supplementation for poor responders - how does it work?, Fertility and Sterility, 94, S86, 10.1016/j.fertnstert.2010.07.330 · doi:10.1016/j.fertnstert.2010.07.330
  25. Hyman, 2013, DHEA supplementation may improve IVF outcome in poor responders: a proposed mechanism, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 168, 49-53, 10.1016/j.ejogrb.2012.12.017 · DOI
  26. Monterde, 2013, Molecular expression of androgen and FSH receptors after follicular priming prior to ICSI cycles - an interim analysis of the IFILL-PRIMI randomised controlled trial, Human Reproduction, 28, i342
  27. Motta, 2006, The use of DHEA in poor responders does not improve IVF outcomes: insights of a pilot study, Fertility and Sterility, 86, S428, 10.1016/j.fertnstert.2006.07.1183 · doi:10.1016/j.fertnstert.2006.07.1183
  28. Singh, 2013, A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve, Gynecological Endocrinology, 29, 989-92, 10.3109/09513590.2013.824957 · doi:10.3109/09513590.2013.824957
  29. Sipe, 2010, Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles, Human Reproduction, 25, 690, 10.1093/humrep/dep442 · DOI
  30. Sönmezer, 2009, Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders, Reproductive BioMedicine Online, 19, 508, 10.1016/j.rbmo.2009.06.006 · DOI
  31. Yeung, 2013, A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency, Journal of Clinical Endocrinology and Metabolism, 98, 380-8, 10.1210/jc.2012-3071 · DOI
  32. Jayaprakasan, 2014, Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): A proof of principle randomised controlled trial protocol, BMJ Open, 4, 10, 10.1136/bmjopen-2014-005767 · DOI
  33. Akhtar, 2013, Heparin for assisted reproduction, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD009452.pub2 · DOI
  34. Buvat, 2003, Androgen therapy with dehydroepiandrosterone, World Journal of Urology, 21, 346, 10.1007/s00345-003-0367-7 · DOI
  35. Casson, 1998, Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial, Fertility and Sterility, 70, 107, 10.1016/S0015-0282(98)00121-6 · DOI · Paper page
  36. Cheong, 2013, Acupuncture and assisted reproductive technology, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006920.pub3 · DOI · Paper page
  37. Fouany, 2013, Is there a role for DHEA supplementation in women with diminished ovarian reserve?, Journal of Assisted Reproduction and Genetics, 30, 1239-44, 10.1007/s10815-013-0018-x · DOI
  38. Frattarelli, 2004, Effect of androgen levels on in vitro fertilization cycles, Fertility and Sterility, 81, 1713, 10.1016/j.fertnstert.2003.11.032 · DOI · Paper page
  39. Garcia-Velasco, 2005, The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study, Fertility and Sterility, 84, 82, 10.1016/j.fertnstert.2005.01.117 · DOI · Paper page
  40. Genazzani, 2001, Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women, Fertility and Sterility, 76, 241, 10.1016/S0015-0282(01)01902-1 · DOI
  41. Gleicher, 2009, Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study, Reproductive Biology and Endocrinology, 7, 108, 10.1186/1477-7827-7-108 · DOI
  42. Gleicher, 2011, Dehydroepiandrosterone, 93, 10.1017/CBO9780511894756.017 · doi:10.1017/cbo9780511894756.017
  43. Gleicher, 2011, The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?, Reproductive Biology and Endocrinology, 9, 116, 10.1186/1477-7827-9-116 · DOI · Paper page
  44. González-Comadran, 2012, Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis, Reproductive BioMedicine Online, 25, 450-9, 10.1016/j.rbmo.2012.07.011 · DOI
  45. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  46. Horie, 1992, Immunohistochemical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium, Human Reproduction, 7, 1461, 10.1093/oxfordjournals.humrep.a137595 · DOI · Paper page
  47. Karp, 2009, Onset of late posttraumatic seizure after dehydroepiandrosterone treatment, Fertility and Sterility, 91, 931.e1, 10.1016/j.fertnstert.2008.08.115 · DOI
  48. Mamas, 2009, Premature ovarian failure and dehydroepiandrosterone, Fertility and Sterility, 91, 644, 10.1016/j.fertnstert.2007.11.055 · DOI
  49. Mamas, 2009, Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results, Current Opinion in Obstetrics and Gynaecology, 21, 306, 10.1097/GCO.0b013e32832e0785 · DOI
  50. Nielsen, 2011, In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA, Molecular Human Reproduction, 17, 63, 10.1093/molehr/gaq073 · DOI · Paper page
  51. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
  52. Ryan, 1968, Steroid formation by isolated and recombined ovarian granulosa and thecal cells, Journal of Clinical Endocrinology & Metabolism, 28, 355, 10.1210/jcem-28-3-355 · DOI · Paper page
  53. Sen, 2010, Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function, Molecular Endocrinology, 24, 1393-403, 10.1210/me.2010-0006 · DOI · Paper page
  54. Sir-Petermann, 2002, Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization, Human Reproduction, 17, 2573, 10.1093/humrep/17.10.2573 · DOI · Paper page
  55. Siristatidis, 2011, Aspirin for in vitro fertilisation, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004832.pub3 · DOI
  56. Somboonporn, 2005, Testosterone for peri- and postmenopausal women, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004509.pub2 · DOI · Paper page
  57. Sunkara, 2011, Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis, Reproductive BioMedicine Online, 22, 545, 10.1016/j.rbmo.2011.01.015 · DOI
  58. Toner, 2002, Progress we can be proud of: U.S. trends in assisted reproduction over the first 20 years, Fertility and Sterility, 78, 943, 10.1016/S0015-0282(02)04197-3 · doi:10.1016/s0015-0282(02)04197-3
  59. Venetis, 2011, Improved probability of pregnancy with transdermal testosterone pretreatment in poor responders treated with GnRH analogues and gonadotrophins for in-vitro fertilization: a meta-analysis, Fertility and Sterility, 96, S56, 10.1016/j.fertnstert.2011.07.214 · DOI
  60. Yakin, 2011, DHEA as a miracle drug in the treatment of poor responders; hype or hope?, Human Reproduction, 26, 1941-4, 10.1093/humrep/der150 · DOI
  61. Zegers-Hochschild, 2009, International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009, Fertility and Sterility, 92, 1520, 10.1016/j.fertnstert.2009.09.009 · DOI · Paper page
  62. Nagels, 2012, Androgens (dehydroepiandrosterone or testosterone) in women undergoing assisted reproduction, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD009749 · DOI

Cited by

See all 156

Metadata

Authors
Nagels, H. E., Rishworth, J. R., Siristatidis, C. S., & Kroon, B.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2015-11-26
Volume
2015
Issue
11
Pages
CD009749-CD009749
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1924114680
Cited by
156
References
10
FWCI
13.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. https://app.cochat.ai/papers/10.1002/14651858.cd009749.pub2
The paper
Nagels, H. E., Rishworth, J. R., Siristatidis, C. S., & Kroon, B. (2015). Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd009749.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.